Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Slides:

Advertisements

Similar presentations

Volume 149, Issue 1, Pages (July 2015)

Advertisements

Fig. 4. Primary human metastatic melanomas contain CCL21-expressing LECs, and expression of VEGFC positively correlates with hallmarks of tumor inflammation.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Volume 17, Issue 5, Pages (May 2015)

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Fig. 5 Maraba induces antitumor T cell immunity.

TIE2hi/VEGFAhi TEMs are present in the TMEM

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Analysis of brain and spinal cord of treated Gaa−/− mice and controls

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 8. In vivo suppression of MM by CMLD

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Intravenous delivery of reovirus to primary and secondary brain tumors

Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Fig. 6. Effects of CD31-NP targeting in perfused human kidneys.

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 4. Specific versus nonspecific NP accumulation.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Macrophage-specific ablation of Vegfa in PyMT implant tumors blocks blood vessel permeability and tumor cell intravasation at the TMEM. A and C, immunofluorescence.

Fig. 1. CD31 is present throughout the human renal vasculature.

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

CD8α+ DC-deficient mice are highly susceptible to Lm infection in the absence of CD169+ macrophages. CD8α+ DC-deficient mice are highly susceptible to.

Fig. 2 STED microscopy of isolated cardiomyocytes from mice treated with MP-rhodamine–loaded CaPs. STED microscopy of isolated cardiomyocytes from mice.

Fig. 5 Hypoxic tumors from obese mice associate with increased production of IL-6 by adipocytes and myeloid cells. Hypoxic tumors from obese mice associate.

Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Fig. 5 EGFR mutation status of patients with NSCLC, detected by histological examination and ARMS PCR. EGFR mutation status of patients with NSCLC, detected.

Cytotoxic therapy induces CSF1-dependent macrophage recruitment.

Fig. 7. KIF11 informs patient prognosis, and targeting improves survival in a preclinical model. KIF11 informs patient prognosis, and targeting improves.

Role of immune and inflammatory cells in lung cancer–associated PH

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Fig. 4. Loss of DLK expression is neuroprotective in the SOD1G93A mouse model of ALS. Loss of DLK expression is neuroprotective in the SOD1G93A mouse model.

Fig. 8 SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and in vivo. SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and.

Fig. 7 CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα. CSPG4-high GBMs show more microglia than CSPG4-low GBMs and express TNFα.

Inhibition of VEGFA or macrophage-specific ablation of Vegfa from TIE2hi/VEGFAhi TMEM macrophages reduces vascular permeability and tumor cell intravasation.

Fig. 7. NAC in breast cancer patients promotes TMEM assembly and increased MENAINV expression. NAC in breast cancer patients promotes TMEM assembly and.

Fig. 3. Morphological changes associated with glial activation were reduced in 16-month-old APP/PS1;C3 KO mice. Morphological changes associated with glial.

Fig. 3. TKI sensitivity assessed by the MANO method.

Fig. 4. Features of PH in LLC1 lung tumor mice.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 6 Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing mice. Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing.

Fig. 3. VEGFR-3 signaling increases infiltration of naïve T cells in a CCR7-dependent manner. VEGFR-3 signaling increases infiltration of naïve T cells.

Evaluation of clinical responses after infusion of CART19 cells

Fig. 4. Acute lung injury in miR-223−/y mice.

Fig. 3 CSF1 is expressed in human melanoma.

Fig. 7 Analysis of the bacterial nidus within tissue abscesses by MALDI IMS demonstrates a paucity of calprotectin signal. Analysis of the bacterial nidus.

Correlation of reovirus RNA/protein with proliferating tumor cells

Fig. 4 cTFH1 cells correlate with a boosting of influenza-specific memory B cells. cTFH1 cells correlate with a boosting of influenza-specific memory B.

Fig. 1 Neutrophils derived from patients with MPNs are associated with an increase in NET formation and a prothrombotic, NET-rich phenotype. Neutrophils.

Fig. 6 Combination therapy with LVSOD2 and LVshCTGF preserves flap volume and reduces fibrosis after RT. Combination therapy with LVSOD2 and LVshCTGF preserves.

Fig. 2. BET inhibition enhances PARPi-induced DNA damage.

Fig. 6. Nontaxane chemotherapies induce TMEM-dependent prometastatic changes in the breast cancer microenvironment. Nontaxane chemotherapies induce TMEM-dependent.

Fig. 3 NK cells are enriched in ICB-sensitive tumors in mouse models and patients and are required for response. NK cells are enriched in ICB-sensitive.

Volume 149, Issue 1, Pages (July 2015)

Fig. 3. Morphological changes associated with glial activation were reduced in 16-month-old APP/PS1;C3 KO mice. Morphological changes associated with glial.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Fig. 4. Paclitaxel promotes the expression of invasive isoforms of MENA in the primary breast cancer microenvironment. Paclitaxel promotes the expression.

Vascular staining in CWR22R xenograft tumors.

HMQ1611 inhibited breast tumor growth in mice.

Fig. 8. TIE2 inhibitor rebastinib eliminates the prometastatic effects of paclitaxel. TIE2 inhibitor rebastinib eliminates the prometastatic effects of.

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 3. Paclitaxel promotes TMEM-dependent vascular permeability, cancer cell dissemination, and metastasis in breast cancer. Paclitaxel promotes TMEM-dependent.

Fig. 5. Paclitaxel promotes breast cancer cell dissemination and metastasis in a MENA-dependent manner. Paclitaxel promotes breast cancer cell dissemination.

Presentation transcript:

Fig. 1. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. Paclitaxel delays tumor growth and promotes infiltration of TIE2hi/VEGFhi macrophages and TMEM assembly. (A) Experimental design and chemotherapy scheme. i.v., intravenously. (B) Mouse models of breast carcinoma, estrogen receptor (ER) status in each model, and cohort sizes. (C) Tumor volume quantification on day 15 of the chemotherapy scheme shown in (A). Mann-Whitney U test. (D) TMEM score, assessed in 10 high-power fields (HPFs) by two pathologists, in mice treated as shown in (A). Mann-Whitney U test. (E) TMEM identification by triple-stain immunohistochemistry (IHC) and representative images for each mouse model. Scale bar, 50 μm. (F) Perivascular IBA1+ macrophages (Mϕ) in 10 HPFs (absolute counts) in PyMT spontaneous and HT17 xenograft tumors, treated with paclitaxel or vehicle control. Mann-Whitney U test. (G) Perivascular TIE2hi/VEGFhi macrophages in 10 HPFs (absolute counts) quantified in PyMT spontaneous and HT17 xenograft tumors, treated with paclitaxel or vehicle control. Mann-Whitney U test. (H) Multichannel IF of IBA1, CD31, TIE2, VEGF, and 4′,6-diamidino-2-phenylindole (DAPI) in two sequential sections of an MMTV-PyMT breast tumor not treated with paclitaxel. Representative VEGFhi/TIE2hi macrophage (also coexpressing IBA1) is encircled with yellow dotted line. Scale bar, 10 μm. (I) Multichannel IF of IBA1, CD31, VEGF, and DAPI in an HT17 xenograft tumor, treated with paclitaxel, demonstrating one VEGFhi and one VEGFlo macrophage in a field. Scale bar, 15 μm. (J and K) Correlations of macrophage infiltration (IBA1+ macrophages or VEGFhi/TIE2hi macrophages) with TMEM score in the PyMT spontaneous (J) and HT17 xenograft (K) models. R2 = Pearson’s coefficient of determination; filled circles, control; open circles, paclitaxel. George S. Karagiannis et al., Sci Transl Med 2017;9:eaan0026 Published by AAAS